Holen Sie sich die Stockscreener-App
9.71
1.94%
0.185
Vorhandelsmarkt:
9.70
-0.01
-0.10%
Schlusskurs vom Vortag:
$9.525
Offen:
$9.53
24-Stunden-Volumen:
1.71M
Relative Volume:
1.00
Marktkapitalisierung:
$574.01M
Einnahmen:
$122.29M
Nettoeinkommen (Verlust:
$122.31M
KGV:
4.5081
EPS:
2.1539
Netto-Cashflow:
$12.00M
1W Leistung:
-19.29%
1M Leistung:
-28.18%
6M Leistung:
+8.73%
1J Leistung:
-13.54%
1-Tages-Spanne:
$9.4703
$9.99
1-Wochen-Bereich:
$9.10
$12.56
52-Wochen-Spanne:
$7.16
$15.04
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
Firmenname
Zevra Therapeutics Inc
Sektor
Branche
Telefon
(888) 958-1253
Adresse
101 FEDERAL STREET, BOSTON
Compare ZVRA vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
9.71 | 563.07M | 122.29M | 122.31M | 12.00M | 2.1539 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Eingeleitet | BTIG Research | Buy |
| 2025-07-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-01-08 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2024-10-07 | Eingeleitet | Guggenheim | Buy |
| 2024-09-24 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-09-24 | Bestätigt | Maxim Group | Buy |
| 2024-04-02 | Bestätigt | Maxim Group | Buy |
| 2024-03-12 | Eingeleitet | William Blair | Outperform |
| 2023-03-17 | Eingeleitet | Maxim Group | Buy |
Alle ansehen
Zevra Therapeutics Inc Aktie (ZVRA) Neueste Nachrichten
U.S. RESEARCH ROUNDUP-Blackstone, Hartford Insurance, Zevra Therapeutics - Bitget
ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law - The AI Journal
ZVRA Maintained by BTIG -- Price Target Lowered to $24.00 - GuruFocus
ZVRA Maintains Buy Rating by Canaccord Genuity -- Price Target L - GuruFocus
Zevra Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Zevra Therapeutics (ZVRA) - PR Newswire
ZVRA Maintained by Guggenheim -- Price Target Lowered to $24 - GuruFocus
Blackstone, Hartford Insurance, Zevra Therapeutics - TradingView
Zevra Europe Entry Plans For Neimann-Pick Drug Put On Hold - insights.citeline.com
Zevra Therapeutics Market Sentiment - Benzinga España
Guggenheim cuts Zevra stock price target to $24 on EU setback - Investing.com
H.C. Wainwright reiterates Zevra stock rating on EU setback By Investing.com - Investing.com Canada
Canaccord cuts Zevra Therapeutics stock price target on Europe sales By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Zevra stock rating on EU setback - Investing.com
Zevra Therapeutics Inc (ZVRA) Institutional Confidence - TradingKey
Zevra Therapeutics Inc (ZVRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Zevra Therapeutics Inc (ZVRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Zevra Therapeutics Inc (ZVRA) Cash Flow - TradingKey
TradingKey - TradingKey
ZVRA|Zevra Therapeutics Inc|Price:9.525|Chg%:-2.995 - TradingKey
GOOGL Stock Price TodayAlphabet Inc Class A News, Charts, Retail Sentiment - Stocktwits
ZVRA Stock Faces Regulatory Setback Amid EMA's Negative Opinion - GuruFocus
ZVRA Faces Setback in Marketing Authorization for Arimoclomol in Europe - GuruFocus
Stocks of Faraday Future and Zevra Therapeutics plunge amid regulatory and investor concerns. - Pluang
Zevra Therapeutics' Arimoclomol Receives Negative Opinion From EU Regulator; Shares Fall - Moomoo
ZVRA Stock Sinks 23% On EU Setback — Analyst Says Risk Is ‘A Headwind, But Not Insurmountable’ - Stocktwits
Zevra Therapeutics (ZVRA) Faces Setback as EMA Panel Rejects Ari - GuruFocus
Zevra Therapeutics Down Over 24%, on Pace for Largest Percent Decrease Since March 2021 -- Data Talk - Moomoo
Zevra Therapeutics Stock Down — European Panel Slams Arimoclomol Bid for Niemann-Pick Type C - Benzinga
Daybu readthrough in EU? Zevra’s NPC bid flounders - BioWorld News
Zevra Slips on Revealing Opinion on Treatment - Baystreet.ca
Zevra Therapeutics Receives EMA Negative Opinion on Arimoclomol Marketing Application - Yahoo Finance
ZVRA Stock Slides As Traders Gauge Pullback And Cash Strength - StocksToTrade
Zevra Therapeutics Shares Sink After Receiving Regulatory Blow - Moomoo
ZVRA Stock Declines Following Unfavorable CHMP Review - GuruFocus
(ZVRA) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
ZVRA Stock Plummets Pre-Market, Heads For Worst Day In Over 5 Years – What’s Driving The Sell-Off? - Stocktwits
Zevra down on EU snub for rare disease therapy (ZVRA:NASDAQ) - Seeking Alpha
Zevra Therapeutics Provides Update On Regulatory Submission For Arimoclomol For The Treatment Of Niemann-Pick Disease Type C In The European Union - marketscreener.com
Zevra Therapeutics to seek re-examination after EU rejects arimoclomol for Niemann-Pick disease treatment - Pluang
Zevra Therapeutics to Seek Re-Examination After Negative CHMP Opinion on Arimoclomol for NPC - Quiver Quantitative
Zevra Therapeutics Provides Update on Regulatory Submission - GlobeNewswire
ZeVra Therapeutics jumps 29% as Miplyffa patent gains FDA exclusivity through 2041 - Pluang
Zevra Therapeutics: Worthy Of An Initial Holding (NASDAQ:ZVRA) - Seeking Alpha
Zevra Therapeutics Announces Details for Q2 2026 Financial Results Call - The Manila Times
Zevra Therapeutics Announces Date for Second Quarter 2026 Financial Results Conference Call - Quiver Quantitative
Is Zevra’s Broad Russell Index Inclusion Reshaping the Investment Case for Zevra Therapeutics (ZVRA)? - Sahm
Zevra Therapeutics (ZVRA) Q4 2024 earnings summary - Quartr
ZVRA Q1 2026 Earnings: Profitability Surprise Amid Missing Revenue DataFinancial Health Score - DonanımHaber
Zevra Therapeutics Inc (ZVRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Form 144 ZEVRA THERAPEUTICS For: 8 July By Investing.com - Investing.com Nigeria
[144] ZEVRA THERAPEUTICS, INC. SEC Filing - Stock Titan
Finanzdaten der Zevra Therapeutics Inc-Aktie (ZVRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):